Hyperthermia With Flexible Electrode-typed 2-MHz Device During Radiotherapy for Solid Tumors
NCT ID: NCT05282784
Last Updated: 2022-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2022-03-10
2022-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiotherapy With Hyperthermia in Recurrent and Radiation-Induced Sarcomas
NCT04398095
Pilot Study of a Catheter-based Ultrasound Hyperthermia System
NCT00911079
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
NCT03989596
Tumor Response in Hypofractionated Radiotherapy
NCT02854449
Study of Electronic Brachytherapy for Cutaneous Basal Cell Carcinoma
NCT02939027
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hyperthermia group
Hyperthermia Radiotherapy
Hyperthermia
Patients will be treated with hyperthermia 2 or 3 times a week. Treatment will be performed for 1 hours per each visit.
Patients will be treated with radiotherapy 5 times a week.
Radiotherapy
Patients will be treated with radiotherapy 5 times a week.
Control
Radiotherapy
Radiotherapy
Patients will be treated with radiotherapy 5 times a week.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hyperthermia
Patients will be treated with hyperthermia 2 or 3 times a week. Treatment will be performed for 1 hours per each visit.
Patients will be treated with radiotherapy 5 times a week.
Radiotherapy
Patients will be treated with radiotherapy 5 times a week.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group (ECOG) score 0-3
* Ability to understand and the willingness to sign a written informed consent documents
Exclusion Criteria
* Active infectious disease
* Pregnant or probability of pregnancy during treatment
* Obesity (BMI ≥35)
* Immunosuppressive drug after organ transplantation
* Autoimmune disease
* Skin injury on treatment area
19 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medicon, Inc.
INDUSTRY
Yonsei Hyperthermia Study Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YURO-H8
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.